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DOI: 10.1039/b916259nThe use of bioabsorbable polymeric scaffolds is being investigated for use in bone tissue engineering
applications, as their properties can be tailored to allow them to degrade and integrate at optimal rates
as bone remodelling is completed. The main goal of this review is to highlight the ‘‘intelligent’’
properties exhibited by chitosan scaffolds and their use in the bone tissue engineering field. To
complement the fast evolution of the bone tissue engineering field, it is important to propose the use of
responsive scaffolds and take advantage of bioinspired materials and their properties as emerging
technologies. There is a growing interest and need for new biomaterials, such as ‘‘smart’’/responsive
materials with the capability to respond to changes in the in vivo environment. This review will provide
an overview of strategies that can modulate bone tissue regeneration by using in situ-forming scaffolds.1. Introduction
Bone is a highly vascular, living and dynamic tissue remarkable
for its combination of mechanical properties and regenerative
capacity. Bone possesses a self-regeneration capacity. However,
there is a limit to the size of bone fractures and defects that can be
self-repaired. This limit is designated as the ‘‘critical size defect’’1–3
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1638 | J. Mater. Chem., 2010, 20, 1638–1645defects, medical intervention is often necessary to repair the bone.
A new field of research that proposes the regeneration of the tissue
instead of its substitution is defined as tissue engineering: ‘‘an
interdisciplinary field of research that applies the principles of
engineering and the life sciences towards the development of
biological substitutes that restore, maintain or improve tissue
function’’.4 Tissue engineering strategies involving scaffolds
include two general categories: (1) the use of acellular matrices
(artificial scaffolds or decellularized tissues), which depend upon
the natural ability of the body to regenerate for proper orientation
and direction of new tissue growth; and (2) the use of scaffolds
with cells.4,5 The most classical paradigm of tissue engineering for
tissue regeneration implies the use of a degradable support or
scaffold material, bioactive factors and cells.4,6,7 Several
characteristics and properties have been described8,9 as sine
qua non requirements for a suitable scaffold to be used in bone-
tissue engineering that will be further discussed on theCatarina M: Alves
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following sections. The main aim behind the different
approaches of bone tissue engineering consists of developing
a functionalized responsive and bioresorbable scaffold able to
stimulate cell adhesion, proliferation and differentiation, with
the objective that osteoblasts produce bone extracellular matrix
(ECM).
Learning from Nature is a concept that implies mimicking
Nature to develop novel functional biomaterials such as bio-
mineralized, ‘‘smart’’ or bonelike composite materials.10–15 The
‘‘smart’’ materials respond to changes of the surrounding envi-
ronment. ‘‘Smart’’ scaffolds and bioreactors are being developed
to enable advanced procedures for delivery of bioactive mole-
cules and mechanical stimuli to cultured cells in order to direct
osteogenic differentiation.13,14,16–19 Increased attention has been
devoted to responsive strategies in vitro, such as the use of flow
perfusion bioreactors. The strategy includes the culture of bone
marrow stromal cells onto scaffolds under flow conditions which
allow a better distribution of nutrients and oxygen and the
necessary mechanical stimuli for cellular differentiation along the
osteogenic lineage.20–22 This approach is an ideal system for the
ex vivo production of bone constructs.23–25 The deeply discussed
typical bone tissue engineering strategy notwithstanding, which
involves the use of a porous scaffold, cells and bioactive mole-
cules, this review will focus on alternative approaches, such as theF: Kurtis Kasper
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This journal is ª The Royal Society of Chemistry 2010use of ‘‘smart’’/responsive acellular scaffolds based on chitosan
for bone tissue engineering applications.
The role of naturally derived materials and environmental
stimuli in modulating bone regeneration will be discussed. While
many excellent biomaterials have been developed in recent years,
their translation into clinical practice has been slow. Chitosan
was the selected natural polymer to be explored in this review
mainly because of its pH responsive properties and biodegrad-
ability. The present review intends to provide an overview of the
current state of the art of naturally derived responsive scaffolds
and in situ-forming concepts for bone tissue engineering appli-
cations, their aims and limitations.2. Scaffolds for bone tissue engineering
The simplest way to define a scaffold for tissue engineering is
that it should provide mechanical support, shape, and cell-scale
architecture for neo-tissue construction in vitro or in vivo as
seeded cells expand and organize.26 Scaffolds mimic the
extracellular matrix and have a crucial role to play in sup-
porting cell growth, differentiation and in delivering growth
factors or other bioactive molecules. The extracellular matrix
(ECM) is involved in bone formation, remodelling, and repair,
and its components include minerals, ions, proteins, and
enzymes.
The traditional requirements for a suitable scaffold for bone
tissue engineering applications include: biocompatibility, biode-
gradability into nontoxic products, and adequate resorption rate
for the repair of bone;13,14 adequate surface characteristics for cell
adhesion and proliferation; an interconnected porous structure
that enable tissue ingrowth, vascularization, exchange of nutri-
ents, oxygen and metabolites;7,28 and suitable mechanical prop-
erties matching those of the native tissue.4,7,27 The biomaterial
must maintain its structural integrity during the first stages of the
new bone formation. In this review we will highlight some
characteristics of acellular scaffolds, such as mechanical prop-
erties and biodegradability.Rui L: Reis
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Table 1 Mechanical properties of cancellous and cortical bone.7,28,33
Compressive strength/MPa Young’s modulus/GPa
Cancellous bone 2–12 0.02–0.5
Cortical bone 100–230 2–30
Table 2 Environmental stimuli that responsive, ‘‘smart’’, ‘‘intelligent’’ or
to which environmentally-sensitive polymers respond.40,46
Physical Chemical Biochemical
Temperature
Ionic strength pH Enzyme ligands
Solvents Specific ions Biochemical agents
Electrical and magnetic fields Chemical agents
Mechanical stress, strain2.1. Mechanical properties
The mechanical properties of bulk materials represent an
important group of characteristics to consider in three-dimen-
sional (3D) artificial ECM (scaffold) design.29 Bulk materials are
fundamental contributors to the mechanical integrity of the
scaffold. This property is especially important for tissue engi-
neering of structural tissues. Thus, the scaffolds should have
mechanical properties resembling those of healthy tissue during
the period of tissue regeneration.7,27 Mechanical strength is
needed for the creation of a 3D structure that will retain its
structure after implantation, particularly in the reconstruction of
hard and load-bearing bone tissues.28
The mechanical properties of the implanted scaffold should
ideally match those of living bone.7,27,30 This demanding balance
represents one limitation of scaffolds intended for bone regen-
eration and generally leads to mechanical biomaterial failure.
Low mechanical strength of porous scaffolds may not be suitable
for the repair of load-bearing tissues in some clinical applica-
tions.31 Depending upon the application, mechanical properties
should be studied keeping in mind the surrounding environment
of the scaffold once placed in an in vivo system. Besides providing
appropriate support in the early stages of healing, the long-term
success of the biomaterial will depend on the efficacious graded
load transfer needed in the later stages of the remodelling
process.32 The mechanical properties of the two types of bone,
i.e., the cortical (compact) and cancellous (spongy) bone, are
listed in Table 1. Highly porous structures with interconnected
pores may fail in these objectives due to poor mechanical prop-
erties.
2.2. Mechanisms of polymer biodegradation
Controlling the degradation of scaffolds to match the rate of
bone growth, to create space for the new bone formation until
full regeneration is reached, remains a major challenge in scaffold
design. The ideal degradable material degrades during its inten-
ded application or immediately after it. The process of polymer
degradation describes the mechanisms through which polymer
chains are cleaved to form oligomers and finally monomers.34
The process of erosion designates the loss of material owing to
monomers and oligomers leaving the polymer.34,35 All biode-
gradable polymers have hydrolysable bonds. Their most
important degradation mechanism is enzymatic hydrolysis. The
latter effect is designated as biodegradation meaning that the
degradation is mediated by a biological process.34 Several factors
influence the kinetics of degradation: the type of chemical bonds,
pH, polymer composition, crystallinity, molecular weight,
porosity, water uptake and location of the implant.34 Hydro-
philic polymers absorb large quantities of water and increase
degradation rates. Resorbable biomaterials have the ability to
resorb over time. This behaviour is necessary to support the1640 | J. Mater. Chem., 2010, 20, 1638–1645gradual ingrowth of cells and complete replacement of a regen-
erated matrix by normal tissue, and to avoid risk of complica-
tions that can be associated with the long-term presence of
foreign material.36 Scaffold evaluation also includes studying the
appropriate degradation rate, which is important because as the
scaffold degrades it is replaced by natural tissue. Biodegradation
is generally required for a tissue engineering scaffold material,
and the degradation rate also needs to match the neo tissue
formation rate to ideally serve the template purpose.27,28,37 Bone
tissue engineering generally requires an artificial extracellular
matrix (scaffold) to regenerate tissue at the site of implantation.
The degradation rate of the scaffolds must be tuned appropri-
ately with the growth rate of the new tissue, by the time the injury
site is totally regenerated the scaffold should be totally
degraded2,13,14 If the degradation is faster than the tissue regen-
eration, the scaffolds will loose its support function for tissue
growth. On the other hand, if the degradation is too slow
compared to tissue formation, the scaffold will compromise the
regeneration of the tissue. This scaffold should disappear
through absorption into the body as the new tissue is regen-
erated.373. ‘‘Smart’’ and responsive scaffolds for bone tissue
engineering applications
Stimuli-responsive, ‘‘smart’’, ‘‘intelligent’’ or environmentally-
sensitive polymers respond with large property changes to small
chemical, physical or biochemical stimuli (Table 2). The concept
of ‘‘smart’’ polymers derived from the development of biomate-
rials that show large conformational changes in response to small
environmental stimuli such as temperature, ionic strength, pH,
or light.26,38 The materials that respond to changes in their
surrounding environment are very attractive because these
changes, mainly in vivo, can be exploited to control parameters
such as drug delivery, cell adhesion, mechanical properties, and
permeability, among others.39 The responses of the polymer may
include precipitation or gelation, reversible adsorption on
a surface, collapse of a hydrogel or surface graft, and alternation
between hydrophilic and hydrophobic states.26,40 Natural poly-
mers may present a more appropriate biological environment to
the cells, since they usually contain domains that can send
important signals to guide the cells at various stages of devel-
opment.41 Collagen and fibrin, natural ECM molecules, have
been used as scaffolds for tissue engineering. They have inter-
esting biological properties for tissue engineering research.42–45
However, their low mechanical properties, instability and dete-
rioration that follow long-term implantation were reported limit
the clinical applications of these natural biomaterials.37This journal is ª The Royal Society of Chemistry 2010
4. Chitosan scaffolds as a responsive biomaterial
Polysaccharides are very attractive for tissue engineering appli-
cations mainly because of their biodegradability, biocompati-
bility and resemblance with the environment of the extracellular
matrix.47,48 Examples of anionic naturally derived polymers are
alginate, hyaluronic acid, chondroitin sulfate and carragenans.48
However chitosan is the only cationic polysaccharide found in
Nature. In the last decade, significant attention has been given to
chitosan-based biomaterials13,49–55 in the field of bone tissue
engineering. This review will focus on chitosan, a polycationic
polymer of natural origin produced by the deacetylation of
chitin, a natural component of crustacea exoskeletons (e.g.
shrimp, crab, lobster, etc.), cell walls of fungi and cuticles of
insects.54,56 The degree of deacetylation represents the proportion
of N-acetyl-D-glucosamine units with respect to the total number
of units.57 Chitosan is degraded, depending on degree of deace-
tylation by enzymes such as lysozyme, N-acetyl-D-glucosamini-
dase and lipases.58 In vivo, chitosan is degraded by enzymatic
hydrolysis, primarily by lysozyme which appears to target acet-
ylated residues.59,60 Degradation kinetics seem to be inversely
related to the degree of deacetylation.59 Lysozyme breaks down
the chitosan polymer chain, diminishing its molecular weight
until it becomes short enough to be processed by cells. Glucos-
amines, the final degradation products of chitosan, are nontoxic,
nonimmunogenic, and noncarcinogenic.61 In vivo, the final
degradation products undergo normal metabolism pathways and
may be incorporated into glycoproteins or excreted as carbon
dioxide gas during respiration.62,63 Lysozyme or muramidase is
an enzyme that catalyzes the hydrolysis of the peptidoglycan
layer of bacterial cell walls.64 This enzyme is active over a broad
pH range from 3 to 8 and is suited to hydrolyze its substrates
both inside and outside cells. Lysozyme is ubiquitous in the
human body.65 It is present in lymphocytes and also secreted by
monocytes, macrophages, and granulocytes, which account for
the largest source.66,67 Monocytes and macrophages are the
dominating contributors to the lysozyme content in serum.66
Human serum lysozyme is found in concentrations from 7 to
13 mg L1.65
Chitosan is a binary polyheterosaccharide of N-acetylglucos-
amine and glucosamine with a b1/4 linkage. The superior tissue
compatibility of chitosan can be partially attributed to its
structural similarity to glycosaminoglycans, which are major
components of the ECM of bone and cartilage.54,68 Chitosan
exhibits a pH-sensitive behavior due to the large quantities of
amino groups on its chains. It is a biocompatible, pH-dependent
cationic polymer, which is insoluble in aqueous solutions above
pH 7.55 However, in dilute or weak acids (pH < 6), the proton-
ated free amino groups of glucosamine facilitate solubility of the
molecule.55 Above pH 6.2 chitosan aqueous solutions lead to the
formation of a hydrated gel-like precipitate.69,70 Due to its
cationic nature and predictable degradation rate, chitosan-based
materials bind growth factors and release them in a controlled
manner.71 Temperature and pH have been extensively studied in
the biomedical field because these two parameters can be easily
controlled and applicable both in vitro and in vivo. Dias et al.72
reported the use of chitosan, a natural and pH-responsive
polymer, grafted onto a biodegradable bioactive composite and
investigated the effect of pH on the biomineralization process.This journal is ª The Royal Society of Chemistry 2010The authors successfully developed ‘‘smart’’ biodegradable
surfaces that respond to pH and that could be used to control the
biomineralization process. They also found that the formation of
biomimetic apatite was dependent on the conformational
changes of chitosan across its critical pH and could be controlled
by pH switching.
Chitosan hydrogels have been used in a number of gene and
drug delivery applications and can deliver growth factors and
pharmaceutical agents in a controlled fashion.58,73,74
Chitosan possesses interesting characteristics, such as its
ability to induce a minimal foreign body reaction, an intrinsic
antibacterial nature,75,76 and the ability to be molded in various
shapes, namely porous structures, suitable for cell ingrowth and
osteoconduction. The mechanical properties of chitosan scaf-
folds are dependent on the pore size and pore orientation.755. Naturally derived in situ forming scaffolds
The goal of the in situ generated implant strategy is used to
engineer biomedical systems at their site of performance using
minimally invasive surgeries.77 Several approaches have been
developed78–80 namely synthetic in situ scaffolding materials that
could deliver cells or provide a structure for tissue infiltration.
Naturally occurring polymers that form thermoreversible gels
include gelatine, carrageenan, cellulose derivatives, xyloglucan
and chitosan with glycerophosphate.69 Moreover, several natural
biomaterials, including collagen, heparin, hyaluronate, and
fibrin have been used for the preparation of injectable in situ-
forming scaffolds.81–86 Besides eliminating the need for ex vivo
implant fabrication, the contact and adhesion between the
biomaterial and native bone may be enhanced with a polymer
formed directly in the bone defect (in situ).87 Current approaches
for implanting medical devices often require complex surgeries.
In the past few years, an increasing number of in situ-forming
systems have been proposed for various biomedical applications,
including drug delivery,88–90 cell encapsulation,69,91 and tissue
repair.83,92,93 There are several possible mechanisms leading to in
situ implant formation. It has become increasingly apparent that
scaffolds for bone tissue engineering applications should provide
more than a temporary 3D structure for developing tissue
construct. Due to the pH-sensitive character of chitosan, this
polymer has great potential to be used in the fabrication of
scaffold and gels that respond to localized conditions of pH in
the human body. Hai Bang Lee et al.94 stated that it is difficult to
perform ex vivo fabrication of certain complex scaffold geome-
tries. As an alternative, they reported the use of in situ-forming
scaffolds as a promising approach for the fabrication of
complicated scaffold geometries. The in situ-forming scaffold is
based on the idea that if a biomaterial undergoes a simple liquid-
to-gel phase transition under physiological conditions, it can be
injected as a liquid, and then form the desired gel in situ.94–96
As previously reported, Ruel-Gariepy et al.69,97 demonstrated
that a mixture of chitosan and glycerol phosphate disodium salt
(b-glycerophosphate) is capable of forming a gel scaffold in situ.
These formulations possess a neutral pH, remain liquid at or
below room temperature, and form monolithic gels at body
temperature.69 The stability of the solution at room temperature
and the gelation time increase as the degree of deacetylation
decreases.69,97 Hai Bang Lee et al.94 described the development ofJ. Mater. Chem., 2010, 20, 1638–1645 | 1641
Fig. 1 Schematic representation of in situ pore forming concept.in situ-forming chitosan gels, and their ability to offer a suitable
scaffold for rat bone marrow stromal cells (rBMSCs) in vitro and
in vivo. The in situ-forming scaffold provides an advantage
compared with traditional scaffolds because it is a noninvasive
alternative for tissue engineering applications. These results
showed that chitosan gel can serve as an in situ-forming gel
scaffold for entrapped rBMSCs in vivo. Studies dealing with the
role of stem/progenitor cells in osteogenesis show that chitosan
has the ability to promote osteogenic progenitor cell recruitment
and attachment, facilitating bone formation.98
As cell and molecular biology converge with materials science
and biomedical engineering, new applications will benefit from
interactive biomaterials that serve to orchestrate cell attachment,
growth and differentiation.26 Recently, a considerable interest
has been given to the development of ‘‘smart’’ materials with the
ability to instruct the behaviour of cells by releasing bioactive
molecules into the local environment.99,1006. In situ pore-forming scaffolds
One of the major challenges of bone tissue engineering is the
development of scaffolds capable of promoting the differentia-
tion of immature progenitor cells down an osteoblastic lineage
(osteoinduction) encouraging the ingrowth of surrounding bone
(osteoconduction) and integration into the surrounding
tissue.101,102 The main goal of the in situ forming scaffolds
strategy is to generate systems at their site of implantation using
minimally invasive surgical procedures or eliminate some steps of
the common strategies used in bone tissue engineering applica-
tions (i.e., cell seeding onto scaffolds ex vivo). Acellular scaffolds
with properties capable to induce bone regeneration could be an
interesting alternative.
One innovative approach was described by the group of
Robert Langer103 for the first time in 2003 proposing in situ pore
formation in a polymer matrix by differential degradation. The
common approaches have been developed to introduce porosity
in a polymer matrix ex vivo and thus facilitate cell seeding either
in vitro or in vivo. In that paper, the authors stated that
controlling pore formation in vivo with specific tissue ingrowth
could be beneficial for bone tissue engineering and presented
a new paradigm for the formation of pores in a polymer matrix
in situ.103 For that, polymer microspheres were used as a pore-
forming agent (porogen).103
It has been demonstrated that hydrophilic polymers such as
chitosan, depending on the processing method and shape present
suitable mechanical properties for bone tissue engineering
applications.13
The inclusion of enzymatically degradable phases in bioma-
terials seems to be a very promising approach to obtain scaffolds
with adequate mechanical properties in the initial stage of
implantation and with a gradual in vivo pore-forming ability.
Martins et al.13 described the development of a biodegradable
matrix, based on chitosan and starch with the ability of forming
a porous structure in situ due to the attack by specific enzymes
present in the human body, taking advantage of the inflamma-
tory response. One of the critical factors that can control bone
tissue regeneration is the degradation rate of the scaffold, as
previously discussed. Tailoring the degradation rate of scaffolds
can facilitate scaffold remodelling and replacement by cells1642 | J. Mater. Chem., 2010, 20, 1638–1645in situ, enhancing bone tissue regeneration. Inflammation is often
viewed as a negative event, but it is fundamental for tissue
regeneration processes.104 Consequently, modulating the
response of implanted material by harnessing characteristics of
the inflammatory response is a powerful tool for driving tissue
regeneration in situ. In this section alternative strategies will be
discussed, such as the potential of using responsive scaffolds to
take advantage of the host inflammatory response and thus
obtain a beneficial outcome for bone tissue engineering appli-
cations. When a material is implanted, an acute inflammation is
initiated involving several cell types.105–107 During inflammation,
neutrophils, monocytes and macrophages are present. These cells
release lysosomal enzymes, such as lysozyme, into the
surrounding tissue.108 It has been suggested that macrophages
and neutrophils produce superoxide, hydrogen peroxide and
hydroxyl free radicals which contribute to the biodegradation of
implanted materials.108 The results of the compressive tests
showed that these materials, based on chitosan and starch,
exhibited very interesting mechanical properties in the dry and
even in the wet state.13 The mechanical properties exhibited by
the scaffolds in the wet state fall in the normal ranges of strength
and modulus for trabecular bone.7,28 This approach seems to be
a promising strategy to produce an in vivo responsive scaffold,
the properties of which may be regulated by the bone regenera-
tion process, with gradual formation of pores in situ and conse-
quent resorption. Using this innovative methodology, authors
aimed at developing a biodegradable matrix based on chitosan
and starch that exhibits suitable mechanical properties at the
initial stage of implantation due to the absence of macroporosity.
In a later in vivo stage, a porous structure develops by specific
enzymes and reactive species present in the human body and
associated to the inflammatory response (Fig. 1).
An alternative approach, involving the concept of bioactivity
and osteoconduction, is to let degradation proceed along
a coordinate of the healing process by making the material
sensitive to the feedback provided by the cells involved in the
healing response.109 A biomimetic scaffold for bone tissue engi-
neering can be any scaffolding material that mimics one or more
characteristics of the natural ECM.110 Functional materials such
as calcium phosphate (CaP)111 and hydroxyapatite112 are often
mixed with bulk materials to mimic bone ECM composition.
CaP has a composition similar to bone mineral and can induce
a biological response identical to that generated in bone
remodelling, which is the process of resorption of old bone
mineral and formation of new bone.113 The biomimetic technique
for coating biomaterials with a bone-like apatite layer is wellThis journal is ª The Royal Society of Chemistry 2010
Fig. 2 Schematic representation of a self-regulated degrading material
with gradual in situ pore formation ability.described18,114–116 and has been applied for the first time to
biodegradable substrates and then to scaffolds by Reis
et al.18,51,58,115,117,118 Biomimetic CaP coating involves immersion
of polymers in simulated body fluid (SBF), a solution with an ion
concentration identical to human plasma. CaP coatings have
shown high efficiency in expediting bone osteoconduction.119
However, for the regeneration of bone, osteoconduction is also
important.100 The incorporation of proteins and enzymes18,120–127
into CaP coatings is well documented. Further studies proposed
an innovative self-regulated degrading material with gradual
in situ pore formation ability for bone tissue engineering appli-
cations. In this study127 one of the main aims was to improve the
osteoconductive properties of chitosan scaffolds. For that,
lysozyme was incorporated into CaP coatings, prepared on the
surface of chitosan scaffolds using a biomimetic coating tech-
nique, with the aim of controlling their degradation rate and
subsequent formation of pores. Furthermore, since lysozyme has
antibacterial properties, these coatings may act as carriers for its
sustained release, preventing infection upon implantation.
Moreover, CaP coatings will enhance the osteoconductive
properties of the chitosan scaffolds. Mineral deposition has been
shown to slow scaffold degradation, probably by creating
a barrier between the scaffold surface and surrounding envi-
ronment.128 In order to avoid this, one possible solution was the
incorporation of the enzyme lysozyme to enhance degradation of
chitosan scaffolds and subsequent formation of pores in situ
(Fig. 2).
Responsive scaffolds for bone tissue engineering do not need
to show the stimulus-dependent change in a reversible fashion.
For example, after the cells or bioactive molecules are delivered,
the scaffolds do not need to reverse the process. As was discussed
above, biodegradability and lack of cytotoxicity are required
characteristics of bone tissue engineering scaffolds.
‘‘Smart’’/responsive polymers may offer promise for revolu-
tionary improvements in tissue engineering scaffolds. Beyond the
physical properties of polymers, a major goal is to improve the
mechanical properties at the initial stage of implantation and if
possible to avoid one of the most critical steps of the tissue
engineering approach, that is the pre-seeding of the scaffolds
with cells. Creating scaffolds with specific properties that per se
could recruit cells to the site of implantation is in our opinion one
of the main current challenges in the field.7. Conclusions and final remarks
Therapies for the treatment of lost tissue include tissue trans-
plantation, surgical reconstruction, drug therapy, synthetic
prostheses and medical devices or associations of those. TheThis journal is ª The Royal Society of Chemistry 2010efforts to address their limitations have elicited the development
of different biomaterials and therapies. In this review we aimed at
presenting as alternative approaches to the engineering of
responsive and in situ-forming scaffolds for bone regeneration.
Chitosan is one of the most promising natural polymers for
bone tissue engineering due, in part, to its particular ability to
form various shapes and structures. The degradation properties
and the ability of forming porous structures and scaffolds in situ
makes chitosan an interesting alternative biomaterial for ortho-
paedic applications.
In the first part of this review, biodegradation and mechanical
properties were highlighted requirements for the implantation of
acellular scaffolds. In the second part, we presented develop-
ments and examples of naturally derived responsive scaffolds for
bone tissue engineering. Finally, we described a new strategy for
bone tissue engineering: the in situ pore-forming concept. The
success of this approach is mainly dictated by the presence of
lysozyme incorporated into the coatings that will grant chitosan
scaffolds with a gradual in vivo pore forming ability and anti-
bacterial activity. Meanwhile, the presence of the CaP coating
will simultaneously enable osteoconductive properties to the
scaffolds. These ‘‘smart’’ and responsive scaffolds, with in situ
pore forming capability and interesting mechanical properties,
seem to be advantageous when compared with other presently
available conventional materials. Despite the recent advances,
future research focusing on the development of novel scaffolds
that per se could recruit desirable cells, regenerate the implan-
tation site and degrade/resorb as a function of healing time still
comprises one of the most demanding and challenging strategies
in the field of bone tissue engineering.References
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